AI study of tumor burden on PSMA PET-CT scans

This study tests an artificial intelligence (AI) tool that may improve how doctors detect prostate cancer using imaging and biopsy information. It could help better identify cancer that is suspected based on PSA blood tests and rectal exam findings.

This trial studies how AI might improve the process of prostate biopsies for people who have had an MRI. It may help if you are scheduled for a biopsy and have not been treated for prostate cancer before.

This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.

This trial uses a computer program (large language model) to help doctors read Chinese PSMA PET/CT reports. The goal is to see if the AI can accurately identify key details about prostate cancer, like where it has spread, which may help make staging and treatment decisions faster.

This trial provides access to a new type of PET/CT scan called 18F-PSMA-1007, which uses a radioactive tracer to find prostate cancer cells that may have spread in the body. The scan may help your doctor plan your treatment more accurately.

This study tests whether using a special PET scan (PSMA PET/CT) to guide prostate biopsy can help find cancer more accurately and in real time. It might help men who need a biopsy because of high PSA levels or abnormal MRI results.